NuVasive reported increased revenue for the second quarter of 2015.
Here are seven things to know from the financial report:
1. The company's revenue increased 6.4 percent to $202.9 million.
2. The GAAP gross profit for the second quarter was $154.4 million and the gross margin was 76.1 percent. The gross profit was up over the same period last year.
3. Net income was $10.3 million, or $0.20 per share for the second quarter. During the second quarter of last year, the company reported $4.1 million net loss.
4. NuVasive reported $306.6 million in cash, cash equivalents and short and long term marketable securities for the quarter.
5. NuVasive updated revenue projects to $810 million for the full year, including $13 million of currency headwinds — approximately 6.2 percent growth compared to last year's revenue.
6. The adjusted EBITDA margin is approximately 25.2 percent, an increase of around 330 basis points compared to last year. The previous expectations for 2015 were 24.6 percent.
7. GAAP earnings per share are estimated around $1.18 for the entire year — higher than the prior expectations of $1.12.
"We are laser-focused on increasing our market share by rapidly developing disruptive technologies and services for spine surgery, expanding our global footprint in existing and new markets, and positioning NuVasive as a commercial powerhouse with integrated sales, service and specialized customer marketing programs," said NuVasive CEO and Chairman Gregory T. Lucier.